When doctors told Australian Greg Jefferys he had hepatitis C and the disease was destroying his liver, the devastating diagnosis was compounded by the cost of a cure.
Unable to afford Sovaldi, hailed as a miracle drug, the 61-year-old flew to India, one of a growing army of patients seeking out low-cost, life-saving medicines on the subcontinent.
Their illnesses vary — hepatitis C, cancer and HIV are among the most common — but they are almost always desperate, seeing in India their only hope to save their life or that of a loved one.
Photo: AFP
They contact underground “buyers clubs,” make the trip to India to buy from a legitimate distributor or seek out shady online pharmacies promising mail-order cures.
“The doctors told me ‘you’ve got Hepatitis C, you’ve probably got liver cancer,’” said Jefferys, a PhD student.
“The chatter was around the new generic versions of Sovaldi being released in India. I hopped on a plane to Chennai and in about two days I had an appointment with a specialist,” he said.
India earned a nickname as “the pharmacy to the developing world” for its tough stance on patents.
Successive governments have taken a view that patents should be granted only for major innovations, not updates to existing compounds — allowing domestic manufacturers to make generic versions of drugs at vastly lower cost.
Sovaldi, chemically known as sofosbuvir, is made by US pharmaceutical giant Gilead and costs US$84,000 for a 12-week cycle of treatment in the US.
Rejected for a patent in India, generic drug makers, some licensed by Gilead, produce versions such as Mylan’s MyHep, that cost less than US$900 a cycle.
“This is something I observe more and more,” said Leena Menghaney, who runs Medecins Sans Frontieres’ Access Campaign in India, which works to broaden access to drugs.
“All kinds of people and patients across the world are starting to access medicines from India. They travel themselves, or they contact a friend,” she said.
More than 130 million people live with chronic hepatitis C worldwide, according to the WHO, and 500,000 die each year from related liver diseases.
Since writing a blog, Jefferys receives 150 e-mails a day from people in the US, Britain and elsewhere asking for help.
When Loon Gangte, a Delhi-based HIV activist, was diagnosed with the virus in 1997, the price of treatment was far beyond his reach.
However, the advent of generic Indian anti-retrovirals saved his life — and made the country a global center for cheap, lifesaving HIV drugs.
Gangte is open about carrying medicines overseas for others and says in a decade he has been stopped just once, at Thai customs, and fined.
Most countries allow patients to import small amounts of medicines only for personal use.
Campaigning by activists like Gangte for better access to HIV treatments helped give rise to so-called buyers clubs, made famous by the 2013 Hollywood film.
“When I saw Dallas Buyers Club, I laughed,” said a woman who asked to be called Meera,who helps one Delhi club by ferrying drugs illegally in her suitcase whenever she travels. “I hate the term ‘drug tourism.’ This is about saving lives.”
Dinesh (not his real name), a long-time HIV campaigner, began working full-time for the same buyers club in August last year, helping people obtain medicines for a nominal fee.
He is not sure how people find him — he has no online presence — but gets requests from as far afield as Austria and Indonesia.
“My family were a bit reluctant, there is always a grey area in this, but I fear only the one above. I feel completely that this is right,” he said.
Pharmaceutical firms say India’s disregard for patents will stifle innovation or make drugs commercially unfeasible — Gilead paid US$11 billion to buy the developer of Sovaldi in 2012.
However, after losing several high-profile patent battles, it appears drugmakers can do little to combat the Indian government’s will or that of overseas patients determined to import drugs.
Gilead spokesman Nick Francis said the company was “aware such activity may occur.”
Perhaps the riskiest route is online pharmacies — a search on e-marketplace IndiaMart turns up dozens claiming to sell generics — with no guarantee against counterfeits.
However, legal channels are springing up, including Delhi-based Ikris Pharma Network, set up in August 2014, which does not sell drugs, but connects patients to genuine distributors.
Founder Praveen Sikri receives 70 calls a day from people struggling to access drugs, including generic Veenat, for cancer.
“Either the drug is not available or it is very expensive,” Sikri said. “We help the patient to get the product in a legalized manner.”
One recent e-mail is from a young man in San Francisco whose grandad desperately needs medicine for a stomach tumor.
In India, one way or another, he will probably be able to find it.
“There are many, many people doing this,” Sikri said.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said that its investment plan in Arizona is going according to schedule, following a local media report claiming that the company is planning to break ground on its third wafer fab in the US in June. In a statement, TSMC said it does not comment on market speculation, but that its investments in Arizona are proceeding well. TSMC is investing more than US$65 billion in Arizona to build three advanced wafer fabs. The first one has started production using the 4-nanometer (nm) process, while the second one would start mass production using the
A TAIWAN DEAL: TSMC is in early talks to fully operate Intel’s US semiconductor factories in a deal first raised by Trump officials, but Intel’s interest is uncertain Broadcom Inc has had informal talks with its advisers about making a bid for Intel Corp’s chip-design and marketing business, the Wall Street Journal reported, citing people familiar with the matter. Nothing has been submitted to Intel and Broadcom could decide not to pursue a deal, according to the Journal. Bloomberg News earlier reported that Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) is in early talks for a controlling stake in Intel’s factories at the request of officials at US President Donald Trump’s administration, as the president looks to boost US manufacturing and maintain the country’s leadership in critical technologies. Trump officials raised the
‘SILVER LINING’: Although the news caused TSMC to fall on the local market, an analyst said that as tariffs are not set to go into effect until April, there is still time for negotiations US President Donald Trump on Tuesday said that he would likely impose tariffs on semiconductor, automobile and pharmaceutical imports of about 25 percent, with an announcement coming as soon as April 2 in a move that would represent a dramatic widening of the US leader’s trade war. “I probably will tell you that on April 2, but it’ll be in the neighborhood of 25 percent,” Trump told reporters at his Mar-a-Lago club when asked about his plan for auto tariffs. Asked about similar levies on pharmaceutical drugs and semiconductors, the president said that “it’ll be 25 percent and higher, and it’ll
CHIP BOOM: Revenue for the semiconductor industry is set to reach US$1 trillion by 2032, opening up opportunities for the chip pacakging and testing company, it said ASE Technology Holding Co (日月光投控), the world’s largest provider of outsourced semiconductor assembly and test (OSAT) services, yesterday launched a new advanced manufacturing facility in Penang, Malaysia, aiming to meet growing demand for emerging technologies such as generative artificial intelligence (AI) applications. The US$300 million facility is a critical step in expanding ASE’s global footprint, offering an alternative for customers from the US, Europe, Japan, South Korea and China to assemble and test chips outside of Taiwan amid efforts to diversify supply chains. The plant, the company’s fifth in Malaysia, is part of a strategic expansion plan that would more than triple
RSS